Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
Nightmares in midlife may point to future cognitive decline, dementia
Jul 12, 2024
The findings were seen in middle-aged and older adults from the general population who did not have Parkinson’s disease.
New report calls for more research on women’s health issues
Jul 12, 2024
The National Academies of Sciences, Engineering and Medicine analysis noted that women are disproportionately affected by chronic illnesses, including Alzheimer’s disease, depression and osteoporosis.
Models constructed to predict decline over time in MCI, mild dementia
Jul 10, 2024
For a hypothetical patient with MCI, a baseline MMSE of 28 and CSF Aβ1-42 of 925 pg/mL, an MMSE of 20 was predicted after 6.0 years and after 8.6 years with a hypothetical treatment.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Vigorous physical activity may preserve cognitive function in high-risk HTN
Jun 24, 2024
High versus low vigorous physical activity was linked to a lower risk of mild cognitive impairment, probable dementia and MCI/probable dementia in a multivariate model.
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
Dementia with Lewy bodies risk down with α-1 adrenergic receptor antagonists
Jun 19, 2024
The risk for developing dementia with Lewy bodies was lower for men newly started on Tz/Dz/Az compared with those taking tamsulosin or 5ARI.